Trial Profile
A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs QBKPN (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Qu Biologics
- 22 Nov 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Sep 2016 New trial record